Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst (NASDAQ:HCAT) and maintained a $16 price target.
August 09, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst (NASDAQ:HCAT) and maintained a $16 price target.
The reiteration of an Overweight rating and a maintained price target of $16 by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Health Catalyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100